Mer­ck dou­bles down on Sky­hawk's tech to drug RNA, promis­ing $600M per au­toim­mune, meta­bol­ic tar­get

Ear­ly col­lab­o­ra­tions with big-name part­ners lent Sky­hawk Ther­a­peu­tics both the en­dorse­ments and the cap­i­tal to pur­sue a small mol­e­cule plat­form for drug­ging RNA. And they soon want­ed more. When Mer­ck signed on to dis­cov­er can­di­dates against neu­rode­gen­er­a­tion and can­cer last Ju­ly, Bio­gen was just ex­pand­ing the list of neu­ro tar­gets they want to go af­ter.

Now Mer­ck is com­ing back for its own round two, adding au­toim­mune and meta­bol­ic dis­eases to the menu.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER